JESSICA ZBERCEA: Open Payments
NPI 1891391470 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 57 payments from 20 companies in 2025. Trend: 2023 $105 · 2024 $922 · 2025 $1,217
Food & beverage: $1,217
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 7 | $176 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $172 |
| Lilly USA, LLC | 8 | $158 |
| Verona Pharma, Inc. | 3 | $86 |
| Novo Nordisk Inc | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| United Therapeutics Corporation | 2 | $61 |
| Insmed, Inc. | 3 | $60 |
| GlaxoSmithKline, LLC. | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
Products named: WINREVAIR, JARDIANCE, Ohtuvayre, DUPIXENT, Tyvaso, Arikayce, KISUNLA, OFEV.
Industry payments across CA — which companies pay providers there.
